Spyre Therapeutics is a biotechnology company dedicated to developing innovative therapies for inflammatory bowel disease (IBD). The company is working to advance a pipeline of long-acting antibodies and rational therapeutic combinations, with a specific focus on harnessing precision immunology approaches. Their lead programs, SPY001 and SPY002, target TL1A and 47 respectively, building on validated mechanisms of action from both clinical and commercial stages. By combining best-in-class antibody engineering with precision medicine, Spyre aims to provide effective solutions for the millions affected by IBD. The organization fosters a collaborative and dynamic work environment, emphasizing professional growth and innovation to deliver impactful therapies for patients.